Search Results 861-870 of 17102 for monoclonal antibody

  1. A Study of Atezolizumab Alone or Combined with Immunomodulatory Drug and/or Daratumumab in Multiple Myeloma Patients - Mayo Clinic

    Receipt of ≥ 2 prior lines of therapy and progressed on treatment with an anti-CD38 monoclonal antibody (Cohort D3). Receipt of ≥ 4 lines of prior therapy ...

  2. CNS Autoantibody and Inflammatory Marker Investigation in Catatonia - Mayo Clinic

    CNS Autoantibody and Inflammatory Marker Investigation in Catatonia · Overview · Participation eligibility · Participating Mayo Clinic locations · More information ...

  3. Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 - Mayo Clinic

    infusion reaction or hypersensitivity (CTCAE Grade 3 or higher) with monoclonal antibody treatment - Clinically significant cardiac disease, including but ...

  4. Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) - Mayo Clinic

    Prior immunotherapy & monoclonal antibody therapy are acceptable. Subjects who received prior cytotoxic chemotherapy after incomplete resection of ...

  5. Brain Metastases Clinical Trials - Mayo Clinic Research

    Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted ...

  6. Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease - Mayo Clinic

    This observational study will collect blood samples to measure sustained antibody concentrations to evaluate seroprevalence and study immunity at 6 and 12 ...

  7. Translational Science - 2020 Archives - Mayo Clinic News Network

    Science Saturday: COVID-19 experimental antibody treatment reaches patients ... Convalescent Plasma: A Therapy for COVID-19? Kate Ledger. April 6, 2020. Science ...

  8. Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) - Mayo Clinic

    Has had prior anti-cancer monoclonal antibody within 4 weeks of Study Day 1 or who has not recovered from adverse events due to agents administered >4 weeks ...

  9. A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy - Mayo Clinic

    History of severe allergic or anaphylactic reactions to monoclonal antibodies or known hypersensitivity to any component of the obinutuzumab infusion; ...

  10. Immune globulin-stwk (intravenous route) - Side effects & uses - Mayo Clinic

    Description. Immune globulin-stwk injection contains antibodies that make your immune system stronger. It is used for patients who have primary humoral ...